S100 calcium binding protein A2Genealiases: CAN19 · S100L
Q-omics provides the consensus-scored S100A2 profile across patient tissues and cancer cell-line models. S100A2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, S100A2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, S100A2 RNA expression shows 16,894 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, KIRC, and ESCA as cancer lineages where S100A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for S100A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes S100A2 survival associations across molecular data types. S100A2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible S100A2 RNA expression–survival associations across cancer types. High S100A2 expression shows unfavorable associations in MESO, KIRC, UVM, LGG, PAAD and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for S100A2 RNA expression.
This table summarizes S100A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for S100A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. S100A2 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in COAD, LUAD and LUSC. The KIRC box plot shows higher S100A2 RNA expression in normal versus tumor tissue (log2 FC = −4.670, t-test p < 0.001).
This table shows molecular features associated with S100A2 in patient tissues and cancer cell lines. In patient samples, S100A2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, S100A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
